GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Inventories, Finished Goods

BioXcel Therapeutics (FRA:BX2) Inventories, Finished Goods : €1.15 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Inventories, Finished Goods?

BioXcel Therapeutics's quarterly finished goods declined from Sep. 2023 (€0.69 Mil) to Dec. 2023 (€0.37 Mil) but then increased from Dec. 2023 (€0.37 Mil) to Mar. 2024 (€1.15 Mil).

BioXcel Therapeutics's annual finished goods increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.56 Mil) but then declined from Dec. 2022 (€0.56 Mil) to Dec. 2023 (€0.37 Mil).


BioXcel Therapeutics Inventories, Finished Goods Historical Data

The historical data trend for BioXcel Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics Inventories, Finished Goods Chart

BioXcel Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods
Get a 7-Day Free Trial - - - 0.56 0.37

BioXcel Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.19 1.15 0.69 0.37 1.15

BioXcel Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


BioXcel Therapeutics (FRA:BX2) Business Description

Traded in Other Exchanges
Address
555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics (FRA:BX2) Headlines

No Headlines